APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pyelonephritis Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Pyelonephritis Drug Market Outlook and Growth Opportunities 2026

19 December 2025197 pages

Choose your research edition.

Industry ResearchPyelonephritis Drug Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Pyelonephritis Drug Industry Growth and Trends Forecast to 203290 pages · $3,450 USDMarket StructureGlobal Pyelonephritis Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032184 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pyelonephritis Drug Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Pyelonephritis Drug Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Pyelonephritis Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Pyelonephritis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Pyelonephritis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Pyelonephritis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Pyelonephritis Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Pyelonephritis Drug market include Merck & Co Inc, The Medicines Company, AstraZeneca Plc, Zavante Therapeutics Inc, MerLion Pharmaceuticals Pte Ltd, Meiji Seika Pharma Co Ltd and Achaogen Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Pyelonephritis Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Pyelonephritis Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Pyelonephritis Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Pyelonephritis Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Pyelonephritis Drug Segment by Company

Merck & Co Inc

The Medicines Company

AstraZeneca Plc

Zavante Therapeutics Inc

MerLion Pharmaceuticals Pte Ltd

Meiji Seika Pharma Co Ltd

Achaogen Inc

Pyelonephritis Drug Segment by Type

Plazomicin Sulfate

Finafloxacin

Fosfomycin Tromethamine

Nacubactam

Others

Pyelonephritis Drug Segment by Application

Hospital

Clinic

Others

Pyelonephritis Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Pyelonephritis Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Pyelonephritis Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Pyelonephritis Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Pyelonephritis Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pyelonephritis Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pyelonephritis Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pyelonephritis Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Pyelonephritis Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Pyelonephritis Drug industry.

Chapter 3: Detailed analysis of Pyelonephritis Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Pyelonephritis Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Pyelonephritis Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Pyelonephritis Drug Industry Trends Table 2. Pyelonephritis Drug Industry Drivers Table 3. Pyelonephritis Drug Industry Opportunities and Challenges Table 4. Pyelonephritis Drug Industry Restraints Table 5. Global Pyelonephritis Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Pyelonephritis Drug Revenue Share by Company (2021-2026) Table 7. Global Pyelonephritis Drug Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Pyelonephritis Drug Sales Volume Share by Company (2021-2026) Table 9. Global Pyelonephritis Drug Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Pyelonephritis Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Pyelonephritis Drug Key Company Manufacturing Base & Headquarters Table 12. Global Pyelonephritis Drug Company, Product Type & Application Table 13. Global Pyelonephritis Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Pyelonephritis Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Plazomicin Sulfate Table 18. Significant Companies of Finafloxacin Table 19. Significant Companies of Fosfomycin Tromethamine Table 20. Significant Companies of Nacubactam Table 21. Significant Companies of Others Table 22. Global Pyelonephritis Drug Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 23. Global Pyelonephritis Drug Sales Volume by Type (2021-2026) & (K Units) Table 24. Global Pyelonephritis Drug Sales Volume by Type (2027-2032) & (K Units) Table 25. Global Pyelonephritis Drug Sales Volume Share by Type (2021-2026) Table 26. Global Pyelonephritis Drug Sales Volume Share by Type (2027-2032) Table 27. Global Pyelonephritis Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Pyelonephritis Drug Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global Pyelonephritis Drug Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global Pyelonephritis Drug Sales Value Share by Type (2021-2026) Table 31. Global Pyelonephritis Drug Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Hospital Table 33. Significant Companies of Clinic Table 34. Significant Companies of Others Table 35. Global Pyelonephritis Drug Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global Pyelonephritis Drug Sales Volume by Application (2021-2026) & (K Units) Table 37. Global Pyelonephritis Drug Sales Volume by Application (2027-2032) & (K Units) Table 38. Global Pyelonephritis Drug Sales Volume Share by Application (2021-2026) Table 39. Global Pyelonephritis Drug Sales Volume Share by Application (2027-2032) Table 40. Global Pyelonephritis Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Pyelonephritis Drug Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global Pyelonephritis Drug Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global Pyelonephritis Drug Sales Value Share by Application (2021-2026) Table 44. Global Pyelonephritis Drug Sales Value Share by Application (2027-2032) Table 45. Global Pyelonephritis Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 46. Global Pyelonephritis Drug Sales by Region (2021-2026) & (K Units) Table 47. Global Pyelonephritis Drug Sales Market Share by Region (2021-2026) Table 48. Global Pyelonephritis Drug Sales by Region (2027-2032) & (K Units) Table 49. Global Pyelonephritis Drug Sales Market Share by Region (2027-2032) Table 50. Global Pyelonephritis Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Pyelonephritis Drug Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global Pyelonephritis Drug Sales Value Share by Region (2021-2026) Table 53. Global Pyelonephritis Drug Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global Pyelonephritis Drug Sales Value Share by Region (2027-2032) Table 55. Global Pyelonephritis Drug Market Average Price (US$/Unit) by Region (2021-2026) Table 56. Global Pyelonephritis Drug Market Average Price (US$/Unit) by Region (2027-2032) Table 57. Global Pyelonephritis Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. Global Pyelonephritis Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Pyelonephritis Drug Sales by Country (2021-2026) & (K Units) Table 60. Global Pyelonephritis Drug Sales Market Share by Country (2021-2026) Table 61. Global Pyelonephritis Drug Sales by Country (2027-2032) & (K Units) Table 62. Global Pyelonephritis Drug Sales Market Share by Country (2027-2032) Table 63. Global Pyelonephritis Drug Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global Pyelonephritis Drug Sales Value Market Share by Country (2021-2026) Table 65. Global Pyelonephritis Drug Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global Pyelonephritis Drug Sales Value Market Share by Country (2027-2032) Table 67. Merck & Co Inc Company Information Table 68. Merck & Co Inc Business Overview Table 69. Merck & Co Inc Pyelonephritis Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. Merck & Co Inc Pyelonephritis Drug Product Portfolio Table 71. Merck & Co Inc Recent Development Table 72. The Medicines Company Company Information Table 73. The Medicines Company Business Overview Table 74. The Medicines Company Pyelonephritis Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. The Medicines Company Pyelonephritis Drug Product Portfolio Table 76. The Medicines Company Recent Development Table 77. AstraZeneca Plc Company Information Table 78. AstraZeneca Plc Business Overview Table 79. AstraZeneca Plc Pyelonephritis Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. AstraZeneca Plc Pyelonephritis Drug Product Portfolio Table 81. AstraZeneca Plc Recent Development Table 82. Zavante Therapeutics Inc Company Information Table 83. Zavante Therapeutics Inc Business Overview Table 84. Zavante Therapeutics Inc Pyelonephritis Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Zavante Therapeutics Inc Pyelonephritis Drug Product Portfolio Table 86. Zavante Therapeutics Inc Recent Development Table 87. MerLion Pharmaceuticals Pte Ltd Company Information Table 88. MerLion Pharmaceuticals Pte Ltd Business Overview Table 89. MerLion Pharmaceuticals Pte Ltd Pyelonephritis Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. MerLion Pharmaceuticals Pte Ltd Pyelonephritis Drug Product Portfolio Table 91. MerLion Pharmaceuticals Pte Ltd Recent Development Table 92. Meiji Seika Pharma Co Ltd Company Information Table 93. Meiji Seika Pharma Co Ltd Business Overview Table 94. Meiji Seika Pharma Co Ltd Pyelonephritis Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Meiji Seika Pharma Co Ltd Pyelonephritis Drug Product Portfolio Table 96. Meiji Seika Pharma Co Ltd Recent Development Table 97. Achaogen Inc Company Information Table 98. Achaogen Inc Business Overview Table 99. Achaogen Inc Pyelonephritis Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Achaogen Inc Pyelonephritis Drug Product Portfolio Table 101. Achaogen Inc Recent Development Table 102. Key Raw Materials Table 103. Raw Materials Key Suppliers Table 104. Pyelonephritis Drug Distributors List Table 105. Pyelonephritis Drug Customers List Table 106. Research Programs/Design for This Report Table 107. Authors List of This Report Table 108. Secondary Sources Table 109. Primary Sources List of Figures Figure 1. Pyelonephritis Drug Product Image Figure 2. Global Pyelonephritis Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pyelonephritis Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Pyelonephritis Drug Sales (2021-2032) & (K Units) Figure 5. Global Pyelonephritis Drug Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Pyelonephritis Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Plazomicin Sulfate Image Figure 10. Finafloxacin Image Figure 11. Fosfomycin Tromethamine Image Figure 12. Nacubactam Image Figure 13. Others Image Figure 14. Global Pyelonephritis Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Pyelonephritis Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global Pyelonephritis Drug Sales Volume Share by Type (2021-2032) Figure 17. Global Pyelonephritis Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Pyelonephritis Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Pyelonephritis Drug Sales Value Share by Type (2021-2032) Figure 20. Hospital Image Figure 21. Clinic Image Figure 22. Others Image Figure 23. Global Pyelonephritis Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Pyelonephritis Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global Pyelonephritis Drug Sales Volume Share by Application (2021-2032) Figure 26. Global Pyelonephritis Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Pyelonephritis Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global Pyelonephritis Drug Sales Value Share by Application (2021-2032) Figure 29. Global Pyelonephritis Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 30. Global Pyelonephritis Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global Pyelonephritis Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global Pyelonephritis Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America Pyelonephritis Drug Sales Value (2021-2032) & (US$ Million) Figure 34. North America Pyelonephritis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe Pyelonephritis Drug Sales Value (2021-2032) & (US$ Million) Figure 36. Europe Pyelonephritis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific Pyelonephritis Drug Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Pyelonephritis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America Pyelonephritis Drug Sales Value (2021-2032) & (US$ Million) Figure 40. South America Pyelonephritis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa Pyelonephritis Drug Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa Pyelonephritis Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA Pyelonephritis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA Pyelonephritis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA Pyelonephritis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada Pyelonephritis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada Pyelonephritis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada Pyelonephritis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico Pyelonephritis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico Pyelonephritis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico Pyelonephritis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany Pyelonephritis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany Pyelonephritis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany Pyelonephritis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France Pyelonephritis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France Pyelonephritis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France Pyelonephritis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. Pyelonephritis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. Pyelonephritis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. Pyelonephritis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy Pyelonephritis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy Pyelonephritis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy Pyelonephritis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain Pyelonephritis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain Pyelonephritis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain Pyelonephritis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia Pyelonephritis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia Pyelonephritis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia Pyelonephritis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands Pyelonephritis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands Pyelonephritis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands Pyelonephritis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries Pyelonephritis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries Pyelonephritis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries Pyelonephritis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China Pyelonephritis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China Pyelonephritis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China Pyelonephritis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan Pyelonephritis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan Pyelonephritis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan Pyelonephritis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea Pyelonephritis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea Pyelonephritis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea Pyelonephritis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India Pyelonephritis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India Pyelonephritis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India Pyelonephritis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia Pyelonephritis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia Pyelonephritis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia Pyelonephritis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia Pyelonephritis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia Pyelonephritis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia Pyelonephritis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil Pyelonephritis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil Pyelonephritis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil Pyelonephritis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina Pyelonephritis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina Pyelonephritis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina Pyelonephritis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile Pyelonephritis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile Pyelonephritis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile Pyelonephritis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia Pyelonephritis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia Pyelonephritis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia Pyelonephritis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru Pyelonephritis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru Pyelonephritis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru Pyelonephritis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Pyelonephritis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia Pyelonephritis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Pyelonephritis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel Pyelonephritis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia Pyelonephritis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia Pyelonephritis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE Pyelonephritis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE Pyelonephritis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE Pyelonephritis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey Pyelonephritis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey Pyelonephritis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey Pyelonephritis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran Pyelonephritis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran Pyelonephritis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran Pyelonephritis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt Pyelonephritis Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt Pyelonephritis Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt Pyelonephritis Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Pyelonephritis Drug Value Chain Figure 128. Manufacturing Cost Structure Figure 129. Pyelonephritis Drug Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • Plazomicin Sulfate
  • Finafloxacin
  • Fosfomycin Tromethamine
  • Nacubactam
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Merck & Co Inc
  • The Medicines Company
  • AstraZeneca Plc
  • Zavante Therapeutics Inc
  • MerLion Pharmaceuticals Pte Ltd
  • Meiji Seika Pharma Co Ltd
  • Achaogen Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Pyelonephritis Drug Sales Value (2021-2032)
  4. 1.2.2 Global Pyelonephritis Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Pyelonephritis Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Pyelonephritis Drug Market Dynamics
  1. 2.1 Pyelonephritis Drug Industry Trends
  2. 2.2 Pyelonephritis Drug Industry Drivers
  3. 2.3 Pyelonephritis Drug Industry Opportunities and Challenges
  4. 2.4 Pyelonephritis Drug Industry Restraints
3 Pyelonephritis Drug Market by Company
  1. 3.1 Global Pyelonephritis Drug Company Revenue Ranking in 2025
  2. 3.2 Global Pyelonephritis Drug Revenue by Company (2021-2026)
  3. 3.3 Global Pyelonephritis Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Pyelonephritis Drug Average Price by Company (2021-2026)
  5. 3.5 Global Pyelonephritis Drug Company Ranking (2024-2026)
  6. 3.6 Global Pyelonephritis Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Pyelonephritis Drug Company Product Type and Application
  8. 3.8 Global Pyelonephritis Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Pyelonephritis Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Pyelonephritis Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Pyelonephritis Drug Market by Type
  1. 4.1 Pyelonephritis Drug Type Introduction
  2. 4.1.1 Plazomicin Sulfate
  3. 4.1.2 Finafloxacin
  4. 4.1.3 Fosfomycin Tromethamine
  5. 4.1.4 Nacubactam
  6. 4.1.5 Others
  7. 4.2 Global Pyelonephritis Drug Sales Volume by Type
  8. 4.2.1 Global Pyelonephritis Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Pyelonephritis Drug Sales Volume by Type (2021-2032)
  10. 4.2.3 Global Pyelonephritis Drug Sales Volume Share by Type (2021-2032)
  11. 4.3 Global Pyelonephritis Drug Sales Value by Type
  12. 4.3.1 Global Pyelonephritis Drug Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Pyelonephritis Drug Sales Value by Type (2021-2032)
  14. 4.3.3 Global Pyelonephritis Drug Sales Value Share by Type (2021-2032)
5 Pyelonephritis Drug Market by Application
  1. 5.1 Pyelonephritis Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Pyelonephritis Drug Sales Volume by Application
  6. 5.2.1 Global Pyelonephritis Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Pyelonephritis Drug Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Pyelonephritis Drug Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Pyelonephritis Drug Sales Value by Application
  10. 5.3.1 Global Pyelonephritis Drug Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Pyelonephritis Drug Sales Value by Application (2021-2032)
  12. 5.3.3 Global Pyelonephritis Drug Sales Value Share by Application (2021-2032)
6 Pyelonephritis Drug Regional Sales and Value Analysis
  1. 6.1 Global Pyelonephritis Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Pyelonephritis Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Pyelonephritis Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Pyelonephritis Drug Sales by Region (2027-2032)
  5. 6.3 Global Pyelonephritis Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Pyelonephritis Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Pyelonephritis Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Pyelonephritis Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Pyelonephritis Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Pyelonephritis Drug Sales Value (2021-2032)
  12. 6.6.2 North America Pyelonephritis Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Pyelonephritis Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Pyelonephritis Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Pyelonephritis Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Pyelonephritis Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Pyelonephritis Drug Sales Value (2021-2032)
  21. 6.9.2 South America Pyelonephritis Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Pyelonephritis Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Pyelonephritis Drug Sales Value Share by Country, 2025 VS 2032
7 Pyelonephritis Drug Country-level Sales and Value Analysis
  1. 7.1 Global Pyelonephritis Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Pyelonephritis Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Pyelonephritis Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Pyelonephritis Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Pyelonephritis Drug Sales by Country (2027-2032)
  6. 7.4 Global Pyelonephritis Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Pyelonephritis Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Pyelonephritis Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Pyelonephritis Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Pyelonephritis Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Pyelonephritis Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Pyelonephritis Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Pyelonephritis Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Pyelonephritis Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Pyelonephritis Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Pyelonephritis Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Pyelonephritis Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Pyelonephritis Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Pyelonephritis Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Pyelonephritis Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Pyelonephritis Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Pyelonephritis Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Pyelonephritis Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Pyelonephritis Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Pyelonephritis Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Pyelonephritis Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Pyelonephritis Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Pyelonephritis Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Pyelonephritis Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Pyelonephritis Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Pyelonephritis Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Pyelonephritis Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Pyelonephritis Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Pyelonephritis Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Pyelonephritis Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Pyelonephritis Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Pyelonephritis Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Pyelonephritis Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Pyelonephritis Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Pyelonephritis Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Pyelonephritis Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Pyelonephritis Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Pyelonephritis Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Pyelonephritis Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Pyelonephritis Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Pyelonephritis Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Pyelonephritis Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Pyelonephritis Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Pyelonephritis Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Pyelonephritis Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Pyelonephritis Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Pyelonephritis Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Pyelonephritis Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Pyelonephritis Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Pyelonephritis Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Pyelonephritis Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Pyelonephritis Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Pyelonephritis Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Pyelonephritis Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Pyelonephritis Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Pyelonephritis Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Pyelonephritis Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Pyelonephritis Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Pyelonephritis Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Pyelonephritis Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Pyelonephritis Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Pyelonephritis Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Pyelonephritis Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Pyelonephritis Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Pyelonephritis Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Pyelonephritis Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Pyelonephritis Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Pyelonephritis Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Pyelonephritis Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Pyelonephritis Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Pyelonephritis Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Pyelonephritis Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Pyelonephritis Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Pyelonephritis Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Pyelonephritis Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Pyelonephritis Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Pyelonephritis Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Pyelonephritis Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Pyelonephritis Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Pyelonephritis Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Pyelonephritis Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Pyelonephritis Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Pyelonephritis Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Pyelonephritis Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Pyelonephritis Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Pyelonephritis Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Pyelonephritis Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Merck & Co Inc
  2. 8.1.1 Merck & Co Inc Company Information
  3. 8.1.2 Merck & Co Inc Business Overview
  4. 8.1.3 Merck & Co Inc Pyelonephritis Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Merck & Co Inc Pyelonephritis Drug Product Portfolio
  6. 8.1.5 Merck & Co Inc Recent Developments
  7. 8.2 The Medicines Company
  8. 8.2.1 The Medicines Company Company Information
  9. 8.2.2 The Medicines Company Business Overview
  10. 8.2.3 The Medicines Company Pyelonephritis Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 The Medicines Company Pyelonephritis Drug Product Portfolio
  12. 8.2.5 The Medicines Company Recent Developments
  13. 8.3 AstraZeneca Plc
  14. 8.3.1 AstraZeneca Plc Company Information
  15. 8.3.2 AstraZeneca Plc Business Overview
  16. 8.3.3 AstraZeneca Plc Pyelonephritis Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 AstraZeneca Plc Pyelonephritis Drug Product Portfolio
  18. 8.3.5 AstraZeneca Plc Recent Developments
  19. 8.4 Zavante Therapeutics Inc
  20. 8.4.1 Zavante Therapeutics Inc Company Information
  21. 8.4.2 Zavante Therapeutics Inc Business Overview
  22. 8.4.3 Zavante Therapeutics Inc Pyelonephritis Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Zavante Therapeutics Inc Pyelonephritis Drug Product Portfolio
  24. 8.4.5 Zavante Therapeutics Inc Recent Developments
  25. 8.5 MerLion Pharmaceuticals Pte Ltd
  26. 8.5.1 MerLion Pharmaceuticals Pte Ltd Company Information
  27. 8.5.2 MerLion Pharmaceuticals Pte Ltd Business Overview
  28. 8.5.3 MerLion Pharmaceuticals Pte Ltd Pyelonephritis Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 MerLion Pharmaceuticals Pte Ltd Pyelonephritis Drug Product Portfolio
  30. 8.5.5 MerLion Pharmaceuticals Pte Ltd Recent Developments
  31. 8.6 Meiji Seika Pharma Co Ltd
  32. 8.6.1 Meiji Seika Pharma Co Ltd Company Information
  33. 8.6.2 Meiji Seika Pharma Co Ltd Business Overview
  34. 8.6.3 Meiji Seika Pharma Co Ltd Pyelonephritis Drug Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Meiji Seika Pharma Co Ltd Pyelonephritis Drug Product Portfolio
  36. 8.6.5 Meiji Seika Pharma Co Ltd Recent Developments
  37. 8.7 Achaogen Inc
  38. 8.7.1 Achaogen Inc Company Information
  39. 8.7.2 Achaogen Inc Business Overview
  40. 8.7.3 Achaogen Inc Pyelonephritis Drug Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Achaogen Inc Pyelonephritis Drug Product Portfolio
  42. 8.7.5 Achaogen Inc Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Pyelonephritis Drug Value Chain Analysis
  2. 9.1.1 Pyelonephritis Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Pyelonephritis Drug Sales Mode & Process
  6. 9.2 Pyelonephritis Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Pyelonephritis Drug Distributors
  9. 9.2.3 Pyelonephritis Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst